BR0107613A - Bloqueio do crescimento de axÈnios mediado por receptor nogo - Google Patents
Bloqueio do crescimento de axÈnios mediado por receptor nogoInfo
- Publication number
- BR0107613A BR0107613A BR0107613-2A BR0107613A BR0107613A BR 0107613 A BR0107613 A BR 0107613A BR 0107613 A BR0107613 A BR 0107613A BR 0107613 A BR0107613 A BR 0107613A
- Authority
- BR
- Brazil
- Prior art keywords
- nogo
- nogo receptor
- blockade
- axon growth
- growth mediated
- Prior art date
Links
- 102000005781 Nogo Receptor Human genes 0.000 title abstract 3
- 108020003872 Nogo receptor Proteins 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 230000028600 axonogenesis Effects 0.000 title abstract 2
- 108010077641 Nogo Proteins Proteins 0.000 abstract 4
- 102000010410 Nogo Proteins Human genes 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 102100029831 Reticulon-4 Human genes 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003952 negative regulation of axon extension Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000023516 stroke disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17570700P | 2000-01-12 | 2000-01-12 | |
| US20736600P | 2000-05-26 | 2000-05-26 | |
| US23637800P | 2000-09-29 | 2000-09-29 | |
| PCT/US2001/001041 WO2001051520A2 (en) | 2000-01-12 | 2001-01-12 | Nogo receptor-mediated blockade of axonal growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0107613A true BR0107613A (pt) | 2002-11-19 |
Family
ID=27390581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0107613-2A BR0107613A (pt) | 2000-01-12 | 2001-01-12 | Bloqueio do crescimento de axÈnios mediado por receptor nogo |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020012965A1 (OSRAM) |
| EP (2) | EP1248803B1 (OSRAM) |
| JP (1) | JP4763207B2 (OSRAM) |
| KR (1) | KR100828058B1 (OSRAM) |
| CN (1) | CN100354307C (OSRAM) |
| AT (1) | ATE466882T1 (OSRAM) |
| AU (1) | AU784349C (OSRAM) |
| BG (1) | BG106907A (OSRAM) |
| BR (1) | BR0107613A (OSRAM) |
| CA (1) | CA2397199C (OSRAM) |
| CZ (1) | CZ20022438A3 (OSRAM) |
| DE (1) | DE60142023D1 (OSRAM) |
| EA (1) | EA008480B1 (OSRAM) |
| EE (1) | EE200200386A (OSRAM) |
| ES (1) | ES2341842T3 (OSRAM) |
| GE (1) | GEP20063830B (OSRAM) |
| HK (1) | HK1051543A1 (OSRAM) |
| HU (1) | HUP0203863A3 (OSRAM) |
| IL (2) | IL150566A0 (OSRAM) |
| IS (1) | IS6455A (OSRAM) |
| MX (1) | MXPA02006885A (OSRAM) |
| NO (1) | NO20023387L (OSRAM) |
| NZ (2) | NZ541694A (OSRAM) |
| PL (1) | PL356887A1 (OSRAM) |
| SK (1) | SK9992002A3 (OSRAM) |
| WO (1) | WO2001051520A2 (OSRAM) |
| YU (1) | YU53502A (OSRAM) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723488B2 (en) | 1998-03-27 | 2010-05-25 | Genentech, Inc. | Monoclonal antibodies to secreted and transmembrane polypeptides |
| US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| AU4682999A (en) | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| US7034132B2 (en) | 2001-06-04 | 2006-04-25 | Anderson David W | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US7119165B2 (en) * | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| EP1248803B1 (en) * | 2000-01-12 | 2010-05-05 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| WO2002081628A2 (en) | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| AU2002211539B2 (en) | 2000-10-06 | 2007-01-25 | Biogen Idec Ma Inc. | Nogo receptor homologs |
| GB0101312D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| GB0101313D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| WO2003018631A2 (en) * | 2001-08-27 | 2003-03-06 | Novartis Ag | Nogo receptor homologues and their use |
| US7309485B2 (en) * | 2001-12-03 | 2007-12-18 | Children's Medical Center Corporation | Reducing myelin-mediated inhibition of axon regeneration |
| FR2841261B1 (fr) * | 2002-06-25 | 2004-08-27 | Univ Pasteur | Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire |
| WO2004014311A2 (en) * | 2002-08-10 | 2004-02-19 | Yale University | Nogo receptor antagonists |
| EP1534736B1 (en) * | 2002-08-10 | 2010-06-02 | Yale University | Nogo receptor antagonists |
| GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| AU2003288434B2 (en) | 2002-12-06 | 2011-03-17 | IRP Health Pty Ltd | Peptides, antibodies thereto, and their use in the treatment of central nervous system damage |
| US7842666B2 (en) * | 2002-12-20 | 2010-11-30 | Research Foundation Of City University Of New York | Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration |
| EP2902491A1 (en) | 2003-03-19 | 2015-08-05 | Biogen MA Inc. | NOGO receptor binding protein |
| AU2004227392A1 (en) * | 2003-04-04 | 2004-10-21 | University Of Rochester | Identification of novel nogo-receptors and methods related thereto |
| RS20050774A (sr) * | 2003-04-16 | 2007-12-31 | Biogen Idec Ma Inc., | Antagonisti nogo receptora za tretman stanja sa amiloidnim plakovima |
| EP1633315A4 (en) * | 2003-05-15 | 2010-09-08 | Univ Leland Stanford Junior | Novel immunomodulating peptide |
| US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
| AU2004247026B2 (en) * | 2003-05-16 | 2009-09-24 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of CNS |
| GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
| US8912144B2 (en) * | 2003-12-16 | 2014-12-16 | Children's Medical Center Corporation | Method for treating stroke via administration of NEP1-40 and inosine |
| WO2005059515A2 (en) * | 2003-12-16 | 2005-06-30 | Children's Medical Center Corporation | Method for treating neurological disorders |
| DK1776136T3 (da) | 2004-06-24 | 2012-12-03 | Biogen Idec Inc | Behandling af tilstande, der involverer demyelinisering |
| US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
| WO2006047049A2 (en) * | 2004-10-01 | 2006-05-04 | Yale University | Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof |
| US20090137484A1 (en) * | 2004-12-01 | 2009-05-28 | National University Of Singapore | Neuronal Network-Interacting Peptide |
| US7893032B2 (en) | 2005-07-07 | 2011-02-22 | Yale University | NgR variants and compositions thereof for suppressing axonal growth inhibition |
| BRPI0613387A2 (pt) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone |
| CA2623635C (en) | 2005-09-26 | 2013-04-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
| JP5829373B2 (ja) | 2006-01-27 | 2015-12-09 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｎｏｇｏレセプターアンタゴニスト |
| JP2009538282A (ja) * | 2006-05-15 | 2009-11-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用 |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| EP2700410A1 (en) | 2006-11-21 | 2014-02-26 | Abbott Laboratories | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NGR) and uses thereof |
| WO2009114197A2 (en) | 2008-03-13 | 2009-09-17 | Yale University | Reactivation of axon growth and recovery in chronic spinal cord injury |
| US20090285803A1 (en) * | 2008-05-13 | 2009-11-19 | Jasvinder Atwal | ANTI-PirB ANTIBODIES |
| US8058406B2 (en) | 2008-07-09 | 2011-11-15 | Biogen Idec Ma Inc. | Composition comprising antibodies to LINGO or fragments thereof |
| JP2015518829A (ja) | 2012-05-14 | 2015-07-06 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト |
| CN104935294B (zh) * | 2014-03-20 | 2018-07-20 | 晶宏半导体股份有限公司 | 振荡器 |
| HK1246810A1 (zh) | 2015-01-08 | 2018-09-14 | Biogen Ma Inc. | Lingo-1对抗药及用於治疗脱髓鞘疾病的用途 |
| CN109354605B (zh) * | 2015-07-17 | 2021-02-05 | 暨南大学 | 一种Nogo-A受体结合肽及其衍生物与应用 |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4839288A (en) | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
| US5466585A (en) | 1986-04-15 | 1995-11-14 | Ciba-Geigy Corporation | Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| CA1315719C (en) | 1988-02-05 | 1993-04-06 | Arthur Bank | Retroviral packaging cell lines and processes of using same |
| CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| ATE124726T1 (de) | 1988-11-04 | 1995-07-15 | Zuerich Erziehungsdirektion | Wachstumsregelfaktoren für neuriten. |
| CA1341050C (en) | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5723719A (en) | 1991-08-08 | 1998-03-03 | Health Research Inc. | Transgenic mouse as model for diseases involving dopaminergic dysfunction |
| DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
| US5449755A (en) | 1991-09-20 | 1995-09-12 | Fred Hutchinson Cancer Research Center | Human cyclin E |
| CA2127450C (en) | 1992-01-07 | 2007-04-17 | Samuel Wadsworth | Transgenic animal models for alzheimer's disease |
| US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| US5731490A (en) | 1992-09-29 | 1998-03-24 | The Ontario Cancer Institute | Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1) |
| JPH07509002A (ja) | 1993-02-11 | 1995-10-05 | エルツィーヒュングスディレクション オブ ザ キャントン チューリッヒ | ニューロトロフィンとミエリン−関連の軸索成長阻害タンパク質に対する抗体との組み合わせが中枢神経系の再生を促進する |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| DK75393D0 (da) | 1993-06-24 | 1993-06-24 | Symbicom Ab | Production of protein |
| ATE214633T1 (de) | 1993-10-28 | 2002-04-15 | Houston Advanced Res Ct | Mikrofabriziertes poröses durchflussgerät |
| AU692841B2 (en) | 1994-03-09 | 1998-06-18 | Abbott Laboratories | Transgenic animals producing oligosaccharides and glycoconjugates |
| FR2718329B1 (fr) | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
| US5908969A (en) | 1994-05-13 | 1999-06-01 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
| WO2000073452A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5728915A (en) | 1995-05-08 | 1998-03-17 | Children's Hospital, Inc. | Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US5961976A (en) | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| US5858708A (en) | 1996-08-12 | 1999-01-12 | Bandman; Olga | Polynucleotides encoding two novel human neuroendocrine-specific proteins |
| WO2000070050A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| NZ522634A (en) * | 1997-12-03 | 2004-02-27 | Genentech Inc | PRO243 encoding a polypeptide with homology to chordin and antibodies and vectors |
| PT1490386E (pt) * | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
| AU762055B2 (en) * | 1998-03-10 | 2003-06-19 | Genentech Inc. | Novel polypeptides and nucleic acids encoding the same |
| WO1999053945A1 (en) | 1998-04-16 | 1999-10-28 | Samuel David | Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
| CA2324297A1 (en) * | 1998-04-23 | 1999-10-28 | Genentech, Inc. | Sh2 domain-containing peptides |
| IL139219A0 (en) * | 1998-04-24 | 2001-11-25 | Genentech Inc | Fizz proteins |
| AU761340B2 (en) * | 1998-06-02 | 2003-06-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU4682999A (en) * | 1998-06-16 | 2000-01-05 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| ES2529196T3 (es) * | 1998-11-06 | 2015-02-17 | University Of Zurich | Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas |
| CA2347835A1 (en) * | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| AU768230B2 (en) * | 1998-12-22 | 2003-12-04 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2004516227A (ja) * | 1999-03-08 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 免疫関連疾患を治療するための組成物と方法 |
| AU2883600A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2383592A1 (en) * | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2001009162A2 (en) * | 1999-07-30 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
| EP1248803B1 (en) * | 2000-01-12 | 2010-05-05 | Yale University | Nogo receptor-mediated blockade of axonal growth |
-
2001
- 2001-01-12 EP EP01942367A patent/EP1248803B1/en not_active Expired - Lifetime
- 2001-01-12 AU AU29401/01A patent/AU784349C/en not_active Ceased
- 2001-01-12 JP JP2001551104A patent/JP4763207B2/ja not_active Expired - Fee Related
- 2001-01-12 EA EA200200755A patent/EA008480B1/ru not_active IP Right Cessation
- 2001-01-12 ES ES01942367T patent/ES2341842T3/es not_active Expired - Lifetime
- 2001-01-12 IL IL15056601A patent/IL150566A0/xx active IP Right Grant
- 2001-01-12 CN CNB018049400A patent/CN100354307C/zh not_active Expired - Fee Related
- 2001-01-12 YU YU53502A patent/YU53502A/sh unknown
- 2001-01-12 HU HU0203863A patent/HUP0203863A3/hu unknown
- 2001-01-12 NZ NZ541694A patent/NZ541694A/en unknown
- 2001-01-12 NZ NZ520065A patent/NZ520065A/en unknown
- 2001-01-12 US US09/758,140 patent/US20020012965A1/en not_active Abandoned
- 2001-01-12 SK SK999-2002A patent/SK9992002A3/sk unknown
- 2001-01-12 KR KR1020027008912A patent/KR100828058B1/ko not_active Expired - Fee Related
- 2001-01-12 CZ CZ20022438A patent/CZ20022438A3/cs unknown
- 2001-01-12 BR BR0107613-2A patent/BR0107613A/pt not_active IP Right Cessation
- 2001-01-12 AT AT01942367T patent/ATE466882T1/de not_active IP Right Cessation
- 2001-01-12 GE GE4901A patent/GEP20063830B/en unknown
- 2001-01-12 WO PCT/US2001/001041 patent/WO2001051520A2/en not_active Ceased
- 2001-01-12 EP EP09170776A patent/EP2163561A1/en not_active Withdrawn
- 2001-01-12 EE EEP200200386A patent/EE200200386A/xx unknown
- 2001-01-12 HK HK03102060.8A patent/HK1051543A1/zh unknown
- 2001-01-12 CA CA2397199A patent/CA2397199C/en not_active Expired - Fee Related
- 2001-01-12 DE DE60142023T patent/DE60142023D1/de not_active Expired - Lifetime
- 2001-01-12 PL PL01356887A patent/PL356887A1/xx unknown
- 2001-01-12 MX MXPA02006885A patent/MXPA02006885A/es not_active Application Discontinuation
-
2002
- 2002-07-03 IL IL150566A patent/IL150566A/en not_active IP Right Cessation
- 2002-07-03 IS IS6455A patent/IS6455A/is unknown
- 2002-07-05 BG BG106907A patent/BG106907A/bg unknown
- 2002-07-12 NO NO20023387A patent/NO20023387L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0107613A (pt) | Bloqueio do crescimento de axÈnios mediado por receptor nogo | |
| WO2003031462A3 (en) | Nogo receptor-mediated blockade of axonal growth | |
| DK1325130T3 (da) | Nogo-Receptorhomologer | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| EP0861261A4 (en) | NUCLEOTID AND PROTEIN SEQUENCES OF DELTA GENES FROM VERTEBRATEN AND METHODS BASED ON THEM | |
| ES2063278T3 (es) | Proteina morfogenetica de hueso. | |
| BR0210282A (pt) | Veìculos de distribuição de fosfato de cálcio para proteìnas osteoindutivas | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| BR9813028A (pt) | Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos | |
| BG101118A (en) | Therapeutical compounds | |
| DE69835680D1 (de) | Therapeutische verwendung von smr1 protein und seinen aktiven derivaten | |
| ATE346151T1 (de) | Monomeres mp52/gdf-5 mit knochenmorphogener aktivität, und dieses enthaltende arzneimittel, zur vorbeugung und behandlung von knochen- und knorpelerkrankungen | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| ATE349521T1 (de) | Mit cd40 und traf interagierende proteine | |
| PL336897A1 (en) | Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts | |
| ATE265225T1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| WO2003003988A3 (en) | Peptides which modulate blood coagulation and methods of use thereof | |
| TR199902564T2 (xx) | K�k�rdak oligomer matris proteininin romatoid artrit tedavisinde kullan�m�. | |
| BR0103257A (pt) | Proteìnas antibióticas humanas | |
| WO2001068693A8 (fr) | Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 10A E 11A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012. |